HNF4{alpha} is a therapeutic target that links AMPK to WNT signalling in early-stage gastric cancer

Conclusions
Our results indicate that HNF4α is a targetable oncoprotein in GC, is regulated by AMPK signalling through AMPKα and resides upstream of WNT signalling. HNF4α may regulate ‘metabolic switch’ characteristic of a general malignant phenotype and its target WNT5A has potential prognostic values. The AMPKα-HNF4α-WNT5A signalling cascade represents a potentially targetable pathway for drug development.

Source: Gut - December 8, 2015 Category: Gastroenterology Authors: Chang, H. R., Nam, S., Kook, M.-C., Kim, K.-T., Liu, X., Yao, H., Jung, H. R., Lemos, R., Seo, H. H., Park, H. S., Gim, Y., Hong, D., Huh, I., Kim, Y.-W., Tan, D., Liu, C.-G., Powis, G., Park, T., Liang, H., Kim, Y. H. Tags: Open access, Pancreatic cancer Stomach Source Type: research